Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Norrie Russell; Eric Fung; and More

Premium

Sialix this week appointed Norrie Russell president and CEO – a newly established full-time position at the company.

Previously Russell was president of Gene Logic, the US operating division of Ocimum Biosolutions. Before that he was president and chief operating officer of NovaRx and chief scientific officer at Invitrogen, now Life Technologies.


Biognosys announced this week that it has added Ignacio Martinez, Hellmut Kirchner, and Harry Welton to its board of directors.

Martinez is a principal at Syngenta Ventures, a participant in the CHF2.7 million ($3 million) funding round the company announced this week (see story this issue). Kirchner is co-founder of the venture fund TVM, also a participant in the funding round. Welton has served as chief financial officer of several biotech firms including Arpida.


Vermillion this week entered into a consulting agreement with Eric Fung under which Fung will continue to serve as the company's chief medical officer and member of its scientific advisory board but will be paid on an hourly basis.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.